DE69826705D1 - Verfahren zur dermalen verabreichung von polypeptiden - Google Patents

Verfahren zur dermalen verabreichung von polypeptiden

Info

Publication number
DE69826705D1
DE69826705D1 DE69826705T DE69826705T DE69826705D1 DE 69826705 D1 DE69826705 D1 DE 69826705D1 DE 69826705 T DE69826705 T DE 69826705T DE 69826705 T DE69826705 T DE 69826705T DE 69826705 D1 DE69826705 D1 DE 69826705D1
Authority
DE
Germany
Prior art keywords
polypeptides
dermal administration
dermal
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69826705T
Other languages
English (en)
Other versions
DE69826705T2 (de
Inventor
Ka Leung
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alza Corp
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Application granted granted Critical
Publication of DE69826705D1 publication Critical patent/DE69826705D1/de
Publication of DE69826705T2 publication Critical patent/DE69826705T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/02—Details
    • A61N1/04—Electrodes
    • A61N1/0404—Electrodes for external use
    • A61N1/0408—Use-related aspects
    • A61N1/0412—Specially adapted for transcutaneous electroporation, e.g. including drug reservoirs
    • A61N1/0416—Anode and cathode
    • A61N1/0424—Shape of the electrode
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/02—Details
    • A61N1/04—Electrodes
    • A61N1/0404—Electrodes for external use
    • A61N1/0408—Use-related aspects
    • A61N1/0428—Specially adapted for iontophoresis, e.g. AC, DC or including drug reservoirs
    • A61N1/0432—Anode and cathode
    • A61N1/044—Shape of the electrode
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/02—Details
    • A61N1/04—Electrodes
    • A61N1/0404—Electrodes for external use
    • A61N1/0408—Use-related aspects
    • A61N1/0428—Specially adapted for iontophoresis, e.g. AC, DC or including drug reservoirs
    • A61N1/0444—Membrane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/20—Applying electric currents by contact electrodes continuous direct currents
    • A61N1/30—Apparatus for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body, or cataphoresis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/327—Applying electric currents by contact electrodes alternating or intermittent currents for enhancing the absorption properties of tissue, e.g. by electroporation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
DE69826705T 1997-11-12 1998-11-03 Verfahren zur dermalen verabreichung von polypeptiden Expired - Lifetime DE69826705T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US96921797A 1997-11-12 1997-11-12
US969217 1997-11-12
PCT/US1998/023298 WO1999024071A1 (en) 1997-11-12 1998-11-03 Method for decreasing self-association of polypeptides

Publications (2)

Publication Number Publication Date
DE69826705D1 true DE69826705D1 (de) 2004-11-04
DE69826705T2 DE69826705T2 (de) 2006-02-23

Family

ID=25515320

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69826705T Expired - Lifetime DE69826705T2 (de) 1997-11-12 1998-11-03 Verfahren zur dermalen verabreichung von polypeptiden
DE69816325T Expired - Lifetime DE69816325T2 (de) 1997-11-12 1998-11-03 Gepufferte arzneistoffformulierungen zur transdermalen verabreichung durch elektrotransport

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69816325T Expired - Lifetime DE69816325T2 (de) 1997-11-12 1998-11-03 Gepufferte arzneistoffformulierungen zur transdermalen verabreichung durch elektrotransport

Country Status (9)

Country Link
US (2) US20020058608A1 (de)
EP (2) EP1030688B1 (de)
JP (2) JP2001522793A (de)
CN (1) CN1278737A (de)
AU (2) AU1375199A (de)
CA (2) CA2309955A1 (de)
DE (2) DE69826705T2 (de)
ES (2) ES2202910T3 (de)
WO (2) WO1999024071A1 (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2501421A1 (en) 1999-05-17 2000-11-23 Conjuchem Inc. Long lasting exendin-4
US7112567B2 (en) 2001-02-16 2006-09-26 Conjuchem Inc. Long lasting glucagon-like peptide 2 (glp-2) for the treatment of gastrointestinal diseases and disorders
DE10114178A1 (de) 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
DE10141650C1 (de) 2001-08-24 2002-11-28 Lohmann Therapie Syst Lts Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen
ITMI20030755A1 (it) * 2003-04-11 2004-10-12 Bottega Verde S R L Peptidi e loro derivati quali inibitori di fenomeni degradativi e composizioni contenenti gli stessi.
JP4458288B2 (ja) * 2003-04-25 2010-04-28 味の素株式会社 コク味付与機能を有する新規糖ペプチド及びペプチド、並びにこれらを使用する食品のコク味付与方法
US7141544B2 (en) * 2003-10-10 2006-11-28 Baxter International, Inc. Stabilization of pharmaceutical protein formulations with small peptides
JP2007519613A (ja) * 2003-10-23 2007-07-19 アルザ・コーポレーシヨン 微小突出部をコーティングするための安定化されたｄｎａの組成物
JP2007511617A (ja) * 2003-11-19 2007-05-10 アルザ・コーポレーシヨン 電気運搬適用のためのポリマーのバッファー調製物の調製法
EP1862174A1 (de) * 2005-03-02 2007-12-05 Ajinomoto Co., Inc. Mittel zur hemmung der insulin-polymer-bildung
AU2014271339B2 (en) * 2005-04-27 2016-11-03 The Procter & Gamble Company Personal care compositions
US20070020220A1 (en) * 2005-04-27 2007-01-25 Procter & Gamble Personal care compositions
US9616011B2 (en) 2005-04-27 2017-04-11 The Procter & Gamble Company Personal care compositions
PT1969004E (pt) 2005-12-28 2011-11-25 Novo Nordisk As Composições que compreendem uma insulina acilada e zinco e método para criar tais composições
JP5550338B2 (ja) 2006-07-31 2014-07-16 ノボ・ノルデイスク・エー／エス ペグ化持続型インスリン
CN101541830A (zh) 2006-09-22 2009-09-23 诺沃-诺迪斯克有限公司 蛋白酶抗性的胰岛素类似物
ES2563038T3 (es) 2007-04-30 2016-03-10 Novo Nordisk A/S Método para secar una composición proteica, una composición proteica seca y una composición farmacéutica que comprende la proteína seca
EP2152243A2 (de) * 2007-04-30 2010-02-17 Novo Nordisk A/S Hochkonzentrierte insulinlösungen und zusammensetzungen
ES2744384T3 (es) * 2007-06-13 2020-02-24 Novo Nordisk As Formulación farmacéutica que comprende un derivado de insulina
JP2009067766A (ja) * 2007-09-12 2009-04-02 Kosumedei Seiyaku Kk 経皮吸収促製剤及びそれを用いた経皮吸収システム
ES2618073T3 (es) 2008-03-14 2017-06-20 Novo Nordisk A/S Análogos de insulina estabilizados frente a proteasas
EP2910571B1 (de) 2008-03-18 2016-10-05 Novo Nordisk A/S Proteasestabilisierte, acylierte insulinanaloga
DK2349324T3 (en) 2008-10-17 2017-12-11 Sanofi Aventis Deutschland COMBINATION OF AN INSULIN AND A GLP-1 AGONIST
US9603904B2 (en) 2008-10-30 2017-03-28 Novo Nordisk A/S Treating diabetes melitus using insulin injections with less than daily injection frequency
KR101836070B1 (ko) 2009-11-13 2018-03-09 사노피-아벤티스 도이칠란트 게엠베하 Ｇｌｐ－１ 작용제, 인슐린 및 메티오닌을 포함하는 약제학적 조성물
JP5973918B2 (ja) 2009-11-13 2016-08-23 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Ｇｌｐ−１アゴニスト及びメチオニンを含む薬学的組成物
PT2611458T (pt) 2010-08-30 2016-12-16 Sanofi Aventis Deutschland Utilização de ave0010 para o fabrico de um medicamento para o tratamento da diabetes mellitus tipo 2
BR112013010345A2 (pt) 2010-10-27 2017-07-25 Novo Nordisk As tratamento de diabetes melitus usando as injeções de insulina administradas com intervalos de variação da injeção
US8361779B2 (en) * 2010-11-24 2013-01-29 Sachem, Inc. Buffer compounds
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
NZ618331A (en) 2011-06-17 2016-04-29 Halozyme Inc Stable formulations of a hyaluronan-degrading enzyme
CN108079281A (zh) 2011-08-29 2018-05-29 赛诺菲-安万特德国有限公司 用于2型糖尿病患者中的血糖控制的药物组合
AR087744A1 (es) 2011-09-01 2014-04-16 Sanofi Aventis Deutschland Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
WO2013082116A1 (en) * 2011-11-28 2013-06-06 Phasebio Pharmaceuticals, Inc. Therapeutic agents comprising insulin amino acid sequences
CA2870313A1 (en) 2012-04-11 2013-10-17 Novo Nordisk A/S Insulin formulations
EP2991672A1 (de) 2013-04-30 2016-03-09 Novo Nordisk A/S Neuartiges verabreichungsschema
WO2015052088A1 (en) 2013-10-07 2015-04-16 Novo Nordisk A/S Novel derivative of an insulin analogue
CN107206058A (zh) 2014-12-12 2017-09-26 赛诺菲-安万特德国有限公司 甘精胰岛素/利西拉来固定比率配制剂
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
MX2019006463A (es) 2016-12-16 2019-08-14 Novo Nordisk As Composiciones farmaceuticas que contienen insulina.
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
CA3116271A1 (en) 2018-10-26 2020-04-30 Novo Nordisk A/S Stable semaglutide compositions and uses thereof

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4767401A (en) * 1975-04-22 1988-08-30 Maurice Seiderman Iontophoretic administration of ionizable or polar medicaments to a mammalian body
US4250878A (en) * 1978-11-22 1981-02-17 Motion Control, Inc. Non-invasive chemical species delivery apparatus and method
US4383529A (en) * 1980-11-03 1983-05-17 Wescor, Inc. Iontophoretic electrode device, method and gel insert
US4371523A (en) * 1980-12-29 1983-02-01 The Regents Of The University Of California Reducing the aggregation of insulin in solution
US4477391A (en) * 1981-08-14 1984-10-16 Collins James F Amino acid isomers, their production and their medicinal use
FI78616C (fi) * 1982-02-05 1989-09-11 Novo Industri As Foerfarande foer framstaellning av en foer infusionsaendamaol avsedd stabiliserad insulinloesning, som har en foerhoejd zinkhalt.
US4963367A (en) * 1984-04-27 1990-10-16 Medaphore, Inc. Drug delivery compositions and methods
US4744819A (en) * 1984-10-23 1988-05-17 Daicel Chemical Industries Ltd. 4-oxo pyridinecarboxamide derivatives as plant growth regulators
US4597966A (en) * 1985-01-09 1986-07-01 Ortho Diagnostic Systems, Inc. Histidine stabilized immunoglobulin and method of preparation
US4722726A (en) * 1986-02-12 1988-02-02 Key Pharmaceuticals, Inc. Method and apparatus for iontophoretic drug delivery
US4752285B1 (en) * 1986-03-19 1995-08-22 Univ Utah Res Found Methods and apparatus for iontophoresis application of medicaments
US4816568A (en) * 1986-05-16 1989-03-28 International Minerals & Chemical Corp. Stabilization of growth hormones
US5042975A (en) * 1986-07-25 1991-08-27 Rutgers, The State University Of New Jersey Iontotherapeutic device and process and iontotherapeutic unit dose
US5250022A (en) * 1990-09-25 1993-10-05 Rutgers, The State University Of New Jersey Iontotherapeutic devices, reservoir electrode devices therefore, process and unit dose
US4878892A (en) * 1987-02-10 1989-11-07 Drug Delivery Systems Inc. Electrolytic transdermal delivery of polypeptides
US4940456A (en) * 1987-02-10 1990-07-10 Dan Sibalis Electrolytic transdermal delivery of proteins
US5032109A (en) * 1987-02-10 1991-07-16 Drug Delivery Systems Inc. Electrolytic transdermal delivery of polypeptides
US5080646A (en) * 1988-10-03 1992-01-14 Alza Corporation Membrane for electrotransport transdermal drug delivery
US5162042A (en) * 1988-07-05 1992-11-10 Alza Corporation Electrotransport transdermal system
US4927408A (en) * 1988-10-03 1990-05-22 Alza Corporation Electrotransport transdermal system
US5147296A (en) * 1988-10-03 1992-09-15 Alza Corporation Membrane for electrotransport transdermal drug delivery
US5496266A (en) * 1990-04-30 1996-03-05 Alza Corporation Device and method of iontophoretic drug delivery
US5088977A (en) * 1988-12-21 1992-02-18 Drug Delivery Systems Inc. Electrical transdermal drug applicator with counteractor and method of drug delivery
WO1990007522A1 (en) * 1988-12-23 1990-07-12 Novo Nordisk A/S Human insulin analogues
DE69010076T2 (de) * 1989-05-25 1994-12-08 Takeda Chemical Industries Ltd Transdermales therapeutisches Mittel.
AU6446190A (en) * 1989-09-15 1991-04-18 Rutgers, The State University Of New Jersey Process for inducing analgesia, peptides and therapeutic compositions
EP0429842B1 (de) * 1989-10-27 1996-08-28 Korea Research Institute Of Chemical Technology Vorrichtung zur transdermalen Applikation von Protein- oder Peptid-Medikamenten
US5167616A (en) * 1989-12-14 1992-12-01 Alza Corporation Iontophoretic delivery method
EP0522043B1 (de) * 1990-03-30 2003-10-15 Alza Corporation Vorrichtung zur iontophoretischen verabreichung
USH1160H (en) * 1990-11-26 1993-04-06 Iontophoretic delivery of peptides
DK10191D0 (da) * 1991-01-22 1991-01-22 Novo Nordisk As Hidtil ukendte peptider
DE10399015I1 (de) * 1991-12-20 2012-05-03 Novo Nordisk As Stabilisierte pharmazeutische formulierung, die wachstumshormon und histidin enthält
DE69320378T2 (de) * 1992-01-21 1999-04-29 Macrochem Corp Iontophoretische verbesserte Verabreichung von Medikamenten
CA2087087C (en) * 1992-01-22 2000-07-18 Burton H. Sage, Jr. Molecules for iontophoretic delivery
US5334038A (en) * 1992-03-27 1994-08-02 International Business Machines Corp. High density connector with sliding actuator
US5312326A (en) * 1992-06-02 1994-05-17 Alza Corporation Iontophoretic drug delivery apparatus
US5534496A (en) * 1992-07-07 1996-07-09 University Of Southern California Methods and compositions to enhance epithelial drug transport
US5533971A (en) * 1993-09-03 1996-07-09 Alza Corporation Reduction of skin irritation during electrotransport
US5387189A (en) * 1993-12-02 1995-02-07 Alza Corporation Electrotransport delivery device and method of making same
US5505715A (en) * 1994-02-25 1996-04-09 Bristol-Myers Squibb Company Iontophoretic transdermal delivery of deoxyspergualin compounds
US5470307A (en) * 1994-03-16 1995-11-28 Lindall; Arnold W. Catheter system for controllably releasing a therapeutic agent at a remote tissue site
US5503632A (en) * 1994-04-08 1996-04-02 Alza Corporation Electrotransport device having improved cathodic electrode assembly
US5504188A (en) * 1994-06-16 1996-04-02 Eli Lilly And Company Preparation of stable zinc insulin analog crystals
US5580856A (en) * 1994-07-15 1996-12-03 Prestrelski; Steven J. Formulation of a reconstituted protein, and method and kit for the production thereof
US5707641A (en) * 1994-10-13 1998-01-13 Pharmaderm Research & Development Ltd. Formulations comprising therapeutically-active proteins or polypeptides
US20020077461A1 (en) * 1996-04-24 2002-06-20 Soren Bjorn Pharmaceutical formulation

Also Published As

Publication number Publication date
DE69816325T2 (de) 2004-04-22
WO1999024015A1 (en) 1999-05-20
DE69816325D1 (de) 2003-08-14
WO1999024071A1 (en) 1999-05-20
DE69826705T2 (de) 2006-02-23
ES2230727T3 (es) 2005-05-01
JP2001522793A (ja) 2001-11-20
EP1030688B1 (de) 2004-09-29
ES2202910T3 (es) 2004-04-01
US20070078096A1 (en) 2007-04-05
CN1278737A (zh) 2001-01-03
CA2309818C (en) 2009-05-05
EP1030688A1 (de) 2000-08-30
CA2309818A1 (en) 1999-05-20
EP1028706A1 (de) 2000-08-23
AU1375199A (en) 1999-05-31
JP2001522815A (ja) 2001-11-20
AU1302499A (en) 1999-05-31
US20020058608A1 (en) 2002-05-16
CA2309955A1 (en) 1999-05-20
EP1028706B1 (de) 2003-07-09

Similar Documents

Publication Publication Date Title
DE69826705D1 (de) Verfahren zur dermalen verabreichung von polypeptiden
DE59813187D1 (de) Verfahren zur herstellung von polypeptiden mit geeigneter glykosilierung
DE69822960D1 (de) Verfahren zur Herstellung von L-Leucin
DE69739258D1 (de) Verfahren zur Herstellung von Polyelektrolyten
DE69802534D1 (de) Verfahren zur herstellung von fluorkohlenwasserstoffen
ATE220558T1 (de) Verbessertes verfahren zur stabilisierung von proteinen
DE69702550D1 (de) Verfahren zur Herstellung von peroxiperfluoropolyxyalkylene
DE69830556D1 (de) Verfahren zur Bestimmung von glykosylierten Proteinen
DE59702177D1 (de) Verfahren zur Herstellung von Hydroxymethylcyclopropan
DE69805887D1 (de) Verfahren zur Herstellung von alpha-Bromolactamderivaten
DE59713017D1 (de) Verfahren zur Herstellung von Alkylhalogensilanen
DE69708032D1 (de) Verfahren zur Herstellung von Trimethylcatecholdiestern
DE59610221D1 (de) Verfahren zur Herstellung von 2-Acetyl-gamma-butyrolacton
DE69806876D1 (de) Verfahren zur Herstellung von 2-Chlorprop-1-en
DE69703764D1 (de) Verfahren zur Herstellung von N-Acetonylbenzamide
DE59807115D1 (de) Verfahren zur Herstellung von Alkoxysilanen
DE59704834D1 (de) Verfahren zur Herstellung von pulverförmigem Zirkondioxid
DE69826915D1 (de) Verfahren zur Herstellung von 3-Methyltetrahydrofuran
DE59806793D1 (de) Verfahren zur Herstellung von Pyridylmethylisothiocyanaten
DE69703599D1 (de) Verfahren zur Herstellung von 2-H-Heptafluorpropan
DE59802385D1 (de) Verfahren zur Herstellung von N-Alkylcarbazolen
DE59801874D1 (de) Verfahren zur kontinuierlichen herstellung von dihydroxydiphenylalkanen
DE69826946D1 (de) Verfahren zur Herstellung von cis-Hexahydroisoindolinen
DE69807409D1 (de) Verfahren zur Herstellung von 7-Octen-1-al
DE69805727D1 (de) Verfahren zur Trennung von Alkylnaphthalenen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition